This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Tuesday's Health Winners & Losers

Updated from 3:05 p.m. EDT

Health-related stock indices were mixed after the long holiday weekend Tuesday, as some stocks climbed with no announcements and others lagged on neutral-to-positive news.

Qiagen (QGEN) announced on Tuesday that it signed a new licensing agreement with Germany's Epigenomics, expanding on one from 2005. The new agreement gives the Netherlands-based company the exclusive worldwide rights to Epigenomics' sample technologies for use in applied testing and in in-vitro molecular diagnostics.

Epigenomics receives an upfront fee and further milestone payments and royalties, though precise financial terms weren't disclosed. A nonexclusive back-license also gives Epigenomics the rights to use the technologies in developmental projects and to commercialize in-vitro molecular diagnostics. Shares of Qiagen were up 28 cents, or 1.7%, to $17.21.

Among those climbing on no apparent news were Affymetrix (AFFX), which rose 77 cents, or 3%, to $26.26, and InterMune (ITMN), which increased 66 cents, or 2.6%, to $26.05. Both stocks are part of the Amex Bioptechnology Index, which was up 6.39, or 0.8%, to 818.62.

Micrus Endovascular (MEND) said Tuesday that it received 510(k) clearance from the Food and Drug Administration for its Enzo steerable microcatheter. However, its stock was down 31 cents, or 1.5%, to $21.04.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs